The peptide directs the conjugate to receptors overexpressed in tumors, such as carbonic anhydrase IX (CAIX) or VEGFR in renal cell carcinoma (RCC), while the linker ensures stable circulation and controlled drug release within the tumor microenvironment. This evidence concerns the gene CA9 and neoplasm.